

# Clinical Policy: Critical Issues in the Management of Adult Patients Presenting to the Emergency Department with Acute Carbon Monoxide Poisoning

**From the American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Critical Issues in the Management of Adult Patients Presenting to the Emergency Department with Carbon Monoxide Poisoning:**

**Stephen J. Wolf, MD (Chair)**

**Eric J. Lavonas, MD**

**Edward P. Sloan, MD, MPH**

**Andy S. Jagoda, MD**

Members of the American College of Emergency Physicians Clinical Policies Committee (Oversight Committee):

Andy S. Jagoda, MD (Chair 2003-2006, Co-Chair 2006-2007)

Wyatt W. Decker, MD (Co-Chair 2006-2007)

Deborah B. Diercks, MD

Jonathan A. Edlow, MD

Francis M. Fesmire, MD

Steven A. Godwin, MD

Sigrid A. Hahn, MD

John M. Howell, MD

J. Stephen Huff, MD

Thomas W. Lukens, MD, PhD

Donna L. Mason, RN, MS, CEN (ENA Representative 2004-2006)

Michael Moon, RN, CNS, MSN, CEN (ENA Representative 2004)

Anthony M. Napoli, MD (EMRA Representative 2004-2006)

Devorah Nazarian, MD

Jim Richmann, RN, BS, MA(c), CEN (ENA Representative 2006-2007)

Scott M. Silvers, MD

Edward P. Sloan, MD, MPH

Molly E. W. Thiessen (EMRA Representative 2006-2007)

Robert L. Wears, MD, MS (Methodologist)

Stephen J. Wolf, MD

Cherri D. Hobgood, MD (Board Liaison 2004-2006)

David C. Seaberg, MD, CPE (Board Liaison 2006-2007)

Rhonda R. Whitson, RHIA, Staff Liaison, Clinical Policies Committee and Subcommittees

Approved by the ACEP Board of Directors, October 5, 2007

Supported by the Emergency Nurses Association, December 9, 2007

Policy statements and clinical policies are the official policies of the American College of Emergency Physicians and, as such, are not subject to the same peer review process as articles appearing in the print journal. Policy statements and clinical policies of ACEP do not necessarily reflect the policies and beliefs of *Annals of Emergency Medicine* and its editors.

0196-0644/\$-see front matter

Copyright © 2008 by the American College of Emergency Physicians.

doi:10.1016/j.annemergmed.2007.10.012

[Ann Emerg Med. 2008;51:138-152.]

## ABSTRACT

This clinical policy focuses on critical issues concerning the management of adult patients presenting to the emergency department (ED) with acute symptomatic carbon monoxide (CO)

poisoning. The subcommittee reviewed the medical literature relevant to the questions posed. The critical questions are:

Should hyperbaric oxygen (HBO<sub>2</sub>) therapy be used for the treatment of patients with acute CO poisoning; and

Can clinical or laboratory criteria identify CO-poisoned patients who are most or least likely to benefit from this therapy?

Recommendations are provided on the basis of the strength of evidence of the literature. Level A recommendations represent patient management principles that reflect a high degree of clinical certainty; Level B recommendations represent patient management principles that reflect moderate clinical certainty; and Level C recommendations represent other patient management strategies that are based on preliminary, inconclusive, or conflicting evidence, or based on committee consensus. This clinical policy is intended for physicians working in hospital-based EDs.

## INTRODUCTION

Carbon monoxide (CO) poisoning is the third leading cause of unintentional poisoning death in the United States.<sup>1</sup> Although death rates have declined by 80% since the introduction of the catalytic converter in 1957, CO poisoning still caused 491 accidental and 1,747 suicidal deaths in 1998.<sup>2</sup> Estimates of diagnosed nonfatal poisoning cases vary widely, from 15,000 to 40,000 events per year.<sup>3,4</sup> However, because misdiagnosis of CO poisoning is common, the true numbers are likely much higher.<sup>5,6</sup>

The mechanisms of toxicity of CO poisoning are not completely understood. CO binds hemoglobin with an affinity approximately 220 times that of oxygen, impairing delivery of oxygen to tissues. CO also binds to myoglobin, worsening the hypoxia in cardiac muscle, and mitochondrial cytochrome oxidase, impairing adenosine triphosphatase production. CO poisoning causes platelet and neutrophil activation, free radical formation, and lipid peroxidation in brain and other tissues, likely through an immunologic mechanism.<sup>7</sup> Acutely, this injures tissue in the brain, heart, and other organs. In addition, a condition of neurologic sequelae has been reported in survivors of acute severe poisoning. Although there are no established diagnostic criteria for this disorder, neurologic sequelae are typified by memory loss, impairments of concentration or language, affective changes such as depression, and parkinsonism.<sup>8,9</sup> Signs of injury may persist from the time of poisoning ("persistent neurologic sequelae") or occur after a latent period of 2 to 21 days ("delayed neurologic sequelae"). The reported incidence of neurologic sequelae varies widely, from 12% to 68% in published clinical trials,<sup>10-16</sup> with spontaneous recovery being reported anywhere from 75% to 100%.<sup>14,16,17</sup>

Administration of oxygen speeds the elimination of CO from the body. Without therapy, the elimination half-life of CO is 4 to 5 hours.<sup>18</sup> Administration of 100% oxygen by tight-fitting face mask at normal atmospheric pressure decreases this half-life to approximately 1 hour.<sup>19</sup> The elimination half-life is further decreased to 20 minutes in a hyperbaric oxygen (HBO<sub>2</sub>) chamber at 2.5 atmospheres absolute pressure.<sup>20</sup> Based in part on the rationale that HBO<sub>2</sub> therapy improves CO elimination, restores tissue oxygenation, improves mitochondrial function, and alters inflammatory response induced by CO, it has been advocated as a therapy for CO poisoning for more than 40 years.<sup>21,22</sup>

Generally, US textbooks, review articles, journal editorials, and commentaries endorse the use of HBO<sub>2</sub> in treating severe CO poisoning.<sup>8,9,23-37</sup> However, the ability of HBO<sub>2</sub> therapy to reduce the incidence and severity of neurologic sequelae has been questioned in other studies.<sup>38-44</sup>

Published CO poisoning treatment algorithms commonly attempt to risk-stratify patients, with the goal of providing HBO<sub>2</sub> therapy only to those patients deemed most likely to benefit.<sup>8,9,25-28,32-37</sup> Recommended indications for the use of HBO<sub>2</sub> vary considerably. Patients with transient loss of consciousness or ongoing altered mental status are generally deemed to be candidates for HBO<sub>2</sub> therapy.<sup>8,9,25-28,32-37</sup> Additionally, metabolic acidosis, hypotension, ataxia, and evidence of myocardial injury are often but variably cited as appropriate treatment indications. Although the ability of carboxyhemoglobin levels to predict mortality, morbidity, or response to therapy is universally considered poor, various treatment algorithms still recommend that HBO<sub>2</sub> therapy be administered, regardless of signs or symptoms of poisoning, if carboxyhemoglobin levels exceed 15%, 20%, 25%, or 40%.<sup>8-10,12-14,25,26,28,36,37</sup> One particularly difficult situation involves pregnant women with apparently mild CO poisoning. CO poisoning can cause fetal demise, limb and vertebral abnormalities, and brain injury.<sup>45-47</sup> Because it is impossible to conduct a detailed neurologic assessment on a fetus, some treatment algorithms recommend HBO<sub>2</sub> treatment for all pregnant women with significant CO exposure on the theory that one is treating the fetus, who may be more severely poisoned than the mother. In this situation, maternal carboxyhemoglobin levels of 15%, 20%, or 25% have been proposed as the threshold for empiric therapy with HBO<sub>2</sub>.<sup>9,26,28,33,34,36,37</sup> Many also point out that HBO<sub>2</sub> therapy is generally safe. The most common complications were anxiety and middle ear barotraumas, reported in 0% to 8% of HBO<sub>2</sub> treatment subjects.<sup>10,12-14</sup> Although older studies report the incidence of seizures to be as high as 5%, only 1 of the 1,037 CO poisoning patients who received HBO<sub>2</sub> in the 4 included trials and a large, consecutive patient case series seized or developed other major complications (0.10%; 95% confidence interval [CI] 0.01% to 0.48%).<sup>10,12-14,48</sup>

Faced with these conflicting recommendations, many emergency physicians are left wondering which patients, if any, require HBO<sub>2</sub> therapy for CO poisoning. Most hospitals in the United States do not have 24-hour HBO<sub>2</sub> chamber availability. Safety and logistical issues involved in procuring HBO<sub>2</sub> therapy vary widely from case to case.

This clinical policy uses an evidence-based approach to evaluate the literature and make recommendations about the management of CO poisoning. The critical questions were generated by the subcommittee, with input from the American College of Emergency Physicians (ACEP) Sections of Toxicology and Hyperbaric Medicine, because they are believed

to be important for emergency physicians initially providing care in the emergency department (ED).

This policy evolved from the 1999 ACEP "Clinical Policy for the Initial Approach to Patients Presenting with Acute Toxic Ingestion or Dermal or Inhalation Exposure."<sup>49</sup>

## METHODOLOGY

This clinical policy was created after careful review and critical analysis of the medical literature. MEDLINE searches for articles published between January 1980 and January 2006 were performed using a combination of key words and their variations, including "carbon monoxide poisoning," and "hyperbaric oxygen." Searches were limited to English-language sources. Additional articles were reviewed from the bibliography of articles cited and from published textbooks and review articles. Subcommittee members also supplied articles from their own files.

The reasons for developing clinical policies in emergency medicine and the approaches used in their development have been enumerated.<sup>50</sup> This policy is a product of the ACEP clinical policy development process and is based on the existing literature; where literature was not available, consensus of emergency physicians, toxicologists, and physicians with hyperbaric medicine expertise was used. Expert review comments were received from individual physicians with topic expertise and from individual members of the American Academy of Clinical Toxicology, American College of Medical Toxicology, Divers Alert Network, and Undersea and Hyperbaric Medical Society. Expert review comments were also received from members of ACEP's Toxicology Section and Hyperbaric Medicine Section. Their responses were used to further refine and enhance this policy. Clinical policies are scheduled for revision every 3 years; however, interim reviews are conducted when technology or the practice environment changes significantly.

All articles used in the formulation of this clinical policy were graded by at least 2 subcommittee members for strength of evidence and classified by the subcommittee members into 3 classes of evidence on the basis of the design of the study, with design 1 representing the strongest evidence and design 3 representing the weakest evidence for therapeutic, diagnostic, and prognostic clinical reports, respectively (Appendix A). Articles were then graded on 6 dimensions thought to be most relevant to the development of a clinical guideline: blinded versus nonblinded outcome assessment, blinded or randomized allocation, direct or indirect outcome measures (reliability and validity), biases (eg, selection, detection, transfer), external validity (ie, generalizability), and sufficient sample size. Articles received a final grade (Class I, II, III) on the basis of a predetermined formula taking into account design and quality of study (Appendix B). Articles with fatal flaws were given an "X" grade and not used in formulating recommendations in this policy. Evidence grading was done with respect to the specific data being extracted, and the specific critical question being reviewed. Thus, the level of evidence for any one study may vary

according to the question, and it is possible for a single article to receive different levels of grading as different critical questions are answered. Question-specific level of evidence grading may be found in the Evidentiary Table included at the end of this policy.

Clinical findings and strength of recommendations regarding patient management were then made according to the following criteria:

**Level A recommendations.** Generally accepted principles for patient management that reflect a high degree of clinical certainty (ie, based on strength of evidence Class I or overwhelming evidence from strength of evidence Class II studies that directly address all of the issues).

**Level B recommendations.** Recommendations for patient management that may identify a particular strategy or range of management strategies that reflect moderate clinical certainty (ie, based on strength of evidence Class II studies that directly address the issue, decision analysis that directly addresses the issue, or strong consensus of strength of evidence Class III studies).

**Level C recommendations.** Other strategies for patient management that are based on preliminary, inconclusive, or conflicting evidence, or in the absence of any published literature, based on panel consensus.

There are certain circumstances in which the recommendations stemming from a body of evidence should not be rated as highly as the individual studies on which they are based. Factors such as heterogeneity of results, uncertainty about effect magnitude and consequences, strength of prior beliefs, and publication bias, among others, might lead to such a downgrading of recommendations.

It is the goal of the Clinical Policies Committee to provide an evidence-based recommendation when the medical literature provides enough quality information to answer a critical question. When the medical literature does not contain enough quality information to answer a critical question, the members of the Clinical Policies Committee believe that it is equally important to alert emergency physicians to this fact.

Recommendations offered in this policy are not intended to represent the only diagnostic and management options that the emergency physician should consider. ACEP clearly recognizes the importance of the individual physician's judgment. Rather, this clinical policy defines for the physician those strategies for which medical literature exists to provide support for answers to the crucial questions addressed in this policy.

**Scope of Application.** This clinical policy is intended for physicians working in hospital-based EDs in a location at which HBO<sub>2</sub> therapy is an available treatment option (whether on site or by reasonably practical patient transfer).

**Inclusion Criteria.** This clinical policy is intended for adult patients presenting to the ED with acute CO poisoning.

**Exclusion Criteria.** This clinical policy is not intended for application to a pediatric population, for fetal exposures, for patients with chronic CO poisoning, or patients with delayed

presentations (greater than 24 hours after cessation of exposure) of CO poisoning.

## CRITICAL QUESTIONS

**Should HBO<sub>2</sub> therapy be used for the treatment of patients with acute CO poisoning; and**

**Can clinical or laboratory criteria identify CO-poisoned patients who are most or least likely to benefit from this therapy?**

**Level A recommendations.** None specified.

**Level B recommendations.** None specified.

**Level C recommendations.**

1. HBO<sub>2</sub> is a therapeutic option for CO-poisoned patients; however, its use cannot be mandated.
2. No clinical variables, including carboxyhemoglobin levels, identify a subgroup of CO-poisoned patients for whom HBO<sub>2</sub> is most likely to provide benefit or cause harm.

Review of the available medical literature found 6 published studies<sup>10,12-14,51,52</sup> and 2 abstracts<sup>16,53</sup> related to this critical question in which treatment outcomes with and without HBO<sub>2</sub> were compared in groups of CO-poisoned patients with similar severity. After structured analysis, the 2 abstracts were automatically assigned a class of X, and 2 articles were downgraded to a class of X and therefore excluded from further analysis.<sup>16,51-53</sup> All identified studies evaluated the effect of HBO<sub>2</sub> on the outcome of neurologic function; none evaluated the effect of HBO<sub>2</sub> on other forms of morbidity or on mortality. Of the 4 remaining studies, 2 supported the use of HBO<sub>2</sub> (1 Class II<sup>10</sup> and 1 Class III<sup>14</sup>) and 2 did not (1 Class II<sup>13</sup> and 1 Class III<sup>12</sup>). These studies have generated great debate over the ideal methodology, variables, and outcomes for studying HBO<sub>2</sub> therapy in CO poisoning.<sup>40,54-60</sup>

In a Class II study, Weaver et al<sup>10</sup> reported a randomized, double-blinded, placebo-controlled, human clinical trial involving 152 patients. All enrolled patients received treatment with either 3 sessions of HBO<sub>2</sub> therapy or normobaric oxygen with sham HBO<sub>2</sub> therapy to maintain blinding. Critically ill patients were included, with half of enrolled patients having lost consciousness and 8% requiring intubation. The follow-up rate was excellent (95%), with assessments performed by trained examiners and compared with age, sex, and education-controlled norms. The definition of neurologic sequelae was fulfilled in self-reported symptomatic patients by an aggregate performance on 6 neuropsychological tests that was at least 1 SD below predicted or by an aggregate score of 2 or more SDs below expected in asymptomatic individuals. Six weeks after poisoning, HBO<sub>2</sub> was associated with a 21.1% (95% CI 6% to 34%) absolute reduction in the rate of neurologic sequelae (46.1% versus 25.0%), with an unadjusted (odds ratio [OR] of 0.39; 95% CI 0.20 to 0.78) favoring treatment with HBO<sub>2</sub>. Twelve months after poisoning, the amount of benefit diminished to an absolute reduction in rate of 14.5% (95% CI 1% to 28%) but remained statistically significant (unadjusted OR 0.46; 95% CI 0.22 to 0.98). Although the incidence of the

primary outcome varied markedly between treatment groups, 6 weeks after poisoning no differences were found in several secondary outcomes: group mean neuropsychological test scores and measurements of various aspects of physical and emotional health were the same in both the HBO<sub>2</sub> and normobaric oxygen groups, and no patient reported CO-related interference with activities of daily living.

Weaver et al<sup>61</sup> analyzed the above clinical trial data with the clinical data from another 91 patients who were eligible but were not enrolled in the study. This Class III study demonstrated that age 36 or older and CO exposure duration of 24 hours or greater were risk factors associated with 6-week cognitive sequelae. Symptoms such as lethargy, dizziness, nausea/vomiting, and loss of consciousness, as well as the initial CoHb level were not independent risk factors associated with 6-week cognitive sequelae. Weaver did not relate any of these clinical factors to sequelae at 6 or 12 months after the CO exposure.

Thom et al<sup>14</sup> also reported a benefit to HBO<sub>2</sub>. In this Class III study, 65 CO-poisoned patients were randomized to a single HBO<sub>2</sub> treatment session or mask oxygen. Blinding was not used, and patients with loss of consciousness were excluded. The primary outcome measure, self-reported symptoms of neurologic sequelae combined with deterioration in at least 1 of 6 neuropsychological tests occurring at any time after treatment, was found in 0% (95% CI 0% to 12%) of the HBO<sub>2</sub>-treated patients and 23% (95% CI 10% to 42%) of the patients treated with ambient pressure oxygen. All patients with reported neurologic sequelae had resolution by 77 days. Of the remaining asymptomatic patients, those treated with ambient pressure performed slightly worse on 1 of 6 neuropsychological tests (trail making) at 4 weeks than those treated with HBO<sub>2</sub> therapy.

One Class II<sup>13</sup> and 1 Class III<sup>12</sup> study reported no difference in outcomes in patients treated with HBO<sub>2</sub>, compared with those receiving normobaric oxygen. In the Class II randomized controlled trial by Scheinkestel et al,<sup>13</sup> 191 patients were treated with continuous oxygen by face mask for 3 days after CO poisoning, with daily trips to the HBO<sub>2</sub> chamber. Patients with severe poisoning were included; more than half were comatose. To maintain blinding, patients randomized to the non-HBO<sub>2</sub> group received "sham" HBO<sub>2</sub> treatments that simulated actual HBO<sub>2</sub> therapy. Additional treatments (up to 6 daily sessions total) were performed in patients without neurologic recovery. This study had a high rate of adverse neurologic outcomes in all patients, regardless of treatment assignment, 74% in HBO<sub>2</sub>-treated patients and 68% in controls (reported OR 1.7; 95% CI 0.8 to 4.0;  $P=0.19$ , NS). This is potentially due to the fact that 73% of all patients enrolled were considered to have "severe CO poisoning," as defined by 1 of 13 criteria. Assessment included 7 neuropsychological tests, with an abnormal score being considered 1 SD below the mean and 2 or more abnormal scores being considered a poor outcome. Endpoints were measured at the completion of therapy and at 1-month follow-

up. At the completion of treatment, the only statistically significant difference between the groups was a favor toward normobaric oxygen therapy in one of the 7 neuropsychological tests (verbal learning). With 54% of subjects lost to follow-up, data on 1-month follow-up were not reported but said to show no difference. Multiple statistical comparisons were reported without apparent planning or statistical correction. Both treatment arms received continuous supplemental mask oxygen for 3 days between their dives or “sham” dives, resulting in greater overall oxygen doses than conventional therapy. As such, comparison of this normobaric oxygen cohort with a more typical normobaric oxygen group receiving ambient air may be speculative.

The second study to report no difference in outcomes is a Class III study by Raphael et al.<sup>12</sup> In this unblinded study, 343 CO-poisoning patients without loss of consciousness were randomized to 1 HBO<sub>2</sub> treatment session or an equivalent duration of mask oxygen. The primary outcome measure was a symptom questionnaire, supplemented by physical and neurologic examination, in an unspecified number of patients. One month after treatment, 32.1% of patients who received HBO<sub>2</sub> therapy and 33.8% of control patients reported neurologic symptoms ( $P=0.75$ , NS,  $\chi^2$ ), and 97% of patients in each group had resumed their previous occupation. Data from this study were republished, with additional subgroup analysis showing no change in outcome.<sup>62</sup>

Unfortunately, none of the identified clinical trials prospectively designated subgroups of patients for separate analysis, weakening the reliability of conclusions based on subgroup analysis. Subject matter experts most commonly identify loss of consciousness, persistent mental status alteration, pregnancy, and high carboxyhemoglobin levels as indications for HBO<sub>2</sub> therapy.

#### Loss of Consciousness

Two studies randomized patients both with and without loss of consciousness from CO poisoning to HBO<sub>2</sub> and non-HBO<sub>2</sub> treatment groups.<sup>10,13</sup>

Weaver et al<sup>10</sup> did not present outcomes data on patients who lost consciousness separately from the aggregate.

Although Scheinkestel et al<sup>13</sup> did not separately report outcomes in patients with and without loss of consciousness, loss of consciousness is one of the 13 criteria used to define “severe CO poisoning” in their study. In this “severely CO-poisoned” subset (N=139; 73% of all subjects), HBO<sub>2</sub> was associated with a 20% absolute increase in poor neurologic outcomes at hospital discharge. Neurologic sequelae at hospital discharge were reported in 85% of HBO<sub>2</sub>-treated and 65% of control patients with severe CO poisoning (reported OR 3.6; 95% CI 1.1 to 11.9;  $P=0.03$ ). It is unclear from the article whether this subgroup analysis and the composite definition of “severe CO poisoning” were planned *a priori* or *post hoc*. If any multiple-measures statistical correction is used, this finding becomes no longer statistically significant, and outcomes at 1-month follow-up were the same in both treatment groups.

As noted above, the 2 Class III studies that enrolled only patients who did not lose consciousness produced conflicting results.<sup>12,14</sup>

In a separate arm of their study, Raphael et al<sup>12</sup> randomized patients who had loss of consciousness or coma (groups B1 and B2, n=286) to receive either 1 or 2 HBO<sub>2</sub> treatments. Although this does not inform the question of whether HBO<sub>2</sub> therapy is better than ambient oxygen treatment for these patients, this study arm did show that outcomes are worse in the more severe poisoning group, regardless of treatment group assignment.

#### Altered Mental Status or Coma

Apart from the above, no study reported separate data about whether HBO<sub>2</sub> therapy affected outcomes differently in patients with or without coma or abnormal mental status on hospital presentation or chamber entry.

#### Age

No study reported separate data about whether HBO<sub>2</sub> therapy affected outcomes differently in patients of advanced age. No child younger than 15 years was enrolled in any trial.

#### Carboxyhemoglobin Level

One Class II<sup>13</sup> and 2 Class III<sup>12,14</sup> studies reported no difference in outcomes, regardless of treatment modality, in patients with high or low carboxyhemoglobin levels.<sup>12-14</sup>

#### Pregnancy

All clinical trials excluded pregnant women. Although fetal outcomes in CO-exposed women have been described in several case series and 1 structured literature review, no study has compared pregnancy outcomes in women of similar poisoning severity treated with different therapeutic options.<sup>45,63-69</sup>

#### Cardiac Arrest

A Class III retrospective case series reported 18 consecutive patients who presented to a single institution after resuscitation from CO-associated cardiac arrest.<sup>70</sup> Despite prompt and aggressive treatment of all patients with HBO<sub>2</sub>, none survived to hospital discharge (0%; 95% CI 0% to 18.5%). However, survival, albeit with devastating neurologic injury, has been reported in a survivor of CO-associated cardiac arrest treated with HBO<sub>2</sub>.<sup>71</sup>

#### Future Areas of Research

Because of the conflicting results of previous clinical trials, an additional large, multicenter human clinical trial is needed. A future trial should include randomization, strict blinding of patients and evaluators to treatment group assignment, an objective assessment of outcome, and serial outcome measurements to evaluate the severity and duration of neurologic sequelae in study subjects. Outcome assessments should include validated instruments that allow

for rigorous quantification of the severity of any impairment. Pretreatment clinical data should be collected and analyzed by prospectively defined subgroups to determine which clinical features best predict response or nonresponse to therapy. In addition to neuropsychological measurements, a future trial should report in detail an assessment of patients' ability to work and perform other activities of daily living and a structured measurement of impact on quality of life. Sufficient data on the severity of impairment are necessary to permit a cost-benefit analysis, which will be particularly important if the number needed to treat is high. Detailed information about patient selection, including patients who declined to participate in the study, is needed to allow comparison between patients included in the study and all CO-poisoned patients treated in EDs. Such a clinical trial will take years to perform. In the interim, analysis of subgroup data from completed studies, using prospectively defined criteria compared across studies, may be useful to identify a group of patients who are either highly likely or highly unlikely to benefit from HBO<sub>2</sub> therapy. In addition, studies about the outcomes and therapy of CO poisoning in children and pregnant women, important patient populations who were excluded from all previous trials, are needed.

*Relevant industry relationships for the following carbon monoxide poisoning subcommittee members are as follows: Dr. Lavonas was the Medical Director of Hyperbaric Medicine at Carolinas Medical Center, Charlotte, NC during the development of this clinical policy.*

*Relevant industry relationships are those relationships with companies associated with products or services that significantly impact the specific aspect of disease addressed in the critical question.*

## REFERENCES

1. United States Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, Compressed Mortality File (CMF) compiled from CMF 1999-2002, Series 20, No. 2H 2004 on CDC WONDER on-line database. Available at: <http://wonder.cdc.gov/mortSQL.html>. Accessed January 13, 2005.
2. Mott JA, Wolfe MI, Alverson CJ, et al. National vehicle emissions policies and practices and declining US carbon monoxide-related mortality. *JAMA*. 2002;288:988-995.
3. Centers for Disease Control and Prevention. Unintentional non-fire-related carbon monoxide exposures - United States, 2001-2003. *MMWR Morb Mortal Wkly Rep*. 2005;54:36-39.
4. Hampson NB. Emergency department visits for carbon monoxide poisoning in the northwest. *J Emerg Med*. 1998;16:695-698.
5. Barret L, Danel V, Faure J. Carbon monoxide poisoning, a diagnosis frequently overlooked. *J Toxicol Clin Toxicol*. 1985;23:309-313.
6. Dolan MC, Haltom TL, Barrows GH, et al. Carboxyhemoglobin levels in patients with flu-like symptoms. *Ann Emerg Med*. 1987;16:782-786.
7. Thom SR, Bhopale VM, Fisher D, et al. Delayed neuropathology after carbon monoxide poisoning is immune-mediated. *Proc Natl Acad Sci U S A*. 2004;101:13660-13665.
8. Thom SR. Hyperbaric-oxygen therapy for acute carbon monoxide poisoning. *N Engl J Med*. 2002;347:1105-1106.
9. Ernst A, Zibrak JD. Carbon monoxide poisoning. *N Engl J Med*. 1998;339:1603-1608.
10. Weaver LK, Hopkins RO, Chan KJ, et al. Hyperbaric oxygen for acute carbon monoxide poisoning. *N Engl J Med*. 2002;347:1057-1067.
11. Parkinson RB, Hopkins RO, Cleavinger HB, et al. White matter hyperintensities and neuropsychological outcome following carbon monoxide poisoning. *Neurology*. 2002;58:1525-1532.
12. Raphael JC, Elkharrat D, Jars-Guinestre MC, et al. Trial of normobaric and hyperbaric oxygen for acute carbon monoxide intoxication. *Lancet*. 1989;2:414-419.
13. Scheinkestel CD, Bailey M, Myles PS, et al. Hyperbaric or normobaric oxygen for acute carbon monoxide poisoning: a randomized controlled clinical trial. *Med J Aust*. 1999;170:203-210.
14. Thom SR, Taber RL, Mendiguren II, et al. Delayed neuropsychologic sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric oxygen. *Ann Emerg Med*. 1995;25:474-480.
15. Deschamps D, Geraud C, Julien H, et al. Memory one month after acute carbon monoxide intoxication: a prospective study. *Occup Environ Med*. 2003;60:212-216.
16. Mathieu D, Wattel F, Mathieu-Nolf M, et al. Randomized prospective study comparing the effect of HBO<sub>2</sub> versus 12 hours of NBO in non comatose CO poisoned patients: results of the interim analysis [abstract]. *Undersea Hyperb Med*. 1996;23:7-8.
17. Choi IS. Delayed neurologic sequelae in carbon monoxide intoxication. *Arch Neurol*. 1983;40:433-435.
18. Peterson JE, Stewart RD. Absorption and elimination of carbon monoxide by inactive young men. *Arch Environ Health*. 1970;21:165-171.
19. Weaver LK, Howe S, Hopkins R, et al. Carboxyhemoglobin half-life in carbon monoxide-poisoned patients treated with 100% oxygen at atmospheric pressure. *Chest*. 2000;117:801-808.
20. Pace N, Strajman E, Walker EL. Acceleration of carbon monoxide elimination in man by high pressure oxygen. *Science*. 1950;111:652-654.
21. Smith G, Sharp GR. Treatment of carbon-monoxide poisoning with oxygen under pressure. *Lancet*. 1960;October:905-906.
22. Helms AK, Whelan HT, Torbey MT. Hyperbaric oxygen therapy of cerebral ischemia. *Cerebrovasc Dis*. 2005;20:417-426.
23. Bohan JS. Benefit of hyperbaric oxygen therapy for acute carbon monoxide poisoning. *J Watch Emerg Med*. 2002;6:81.
24. Brett AS. Hyperbaric oxygen for carbon monoxide poisoning. *J Watch*. October 15, 2002.
25. Hampson NB, Mathieu D, Piantadosi CA, et al. Carbon monoxide poisoning: interpretation of randomized clinical trials and unresolved treatment issues. *Undersea Hyperb Med*. 2001;28:157-164.
26. Jones AL, Flanagan RJ. Hyperbaric oxygen. In: Dart RC, ed. *Medical Toxicology*. Philadelphia, PA: Lippincott, Williams & Wilkins; 2004:217-220.
27. Lavonas EJ. Carbon monoxide poisoning. In: Shannon MW, Borron SW, Burns M, eds. *Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose*. Philadelphia, PA: Elsevier; 2006.
28. Moon RE, Camporesi EM. Clinical care at altered environmental pressure. In: Miller RD, ed. *Anesthesia*. Philadelphia, PA: Churchill Livingstone; 2000:2271-2301.
29. Nelson LS, Hoffman RS. Inhaled toxins. In: Marx JA, ed. *Rosen's Emergency Medicine: Concepts and Clinical Practice*. Philadelphia, PA: Mosby; 2006:2432-2441.

30. Piantadosi CA. Carbon monoxide poisoning. *N Engl J Med*. 2002; 347:1054-1055.
31. Pitts S. 3 hyperbaric oxygen treatments reduced cognitive sequelae of acute carbon monoxide poisoning. *ACP J Club*. 2003; 138:67.
32. Thom SR. Carbon monoxide poisoning. In: Brent J, Wallace KL, Burkhart KK, et al, eds. *Critical Care Toxicology: Diagnosis and Management of the Critically Poisoned Patient*. Philadelphia, PA: Elsevier/Mosby; 2005:975-985.
33. Tomaszewski CA. Carbon monoxide. In: Ford MD, Delaney KA, Ling LJ, et al, eds. *Clinical Toxicology*. Philadelphia, PA: Saunders; 2001:657-667.
34. Tomaszewski C. Carbon monoxide. In: Goldfrank LR, Flomenbaum NE, Lewin NA, et al, eds. *Goldfrank's Toxicological Emergencies*. New York, NY: McGraw-Hill; 2002:1478-1491.
35. Thom SR, Weaver LK. Carbon monoxide poisoning. In: Feldmeier JJ, ed. *Hyperbaric Oxygen 2003 Indications and Results: The Hyperbaric Oxygen Therapy Committee Report*. Kensington, MD: Undersea and Hyperbaric Medical Society; 2003:11-17.
36. VanMeter KW. Carbon monoxide poisoning. In: Tintinalli JE, ed. *Emergency Medicine: A Comprehensive Study Guide*. New York, NY: McGraw Hill; 2000:1302-1306.
37. Weaver LK. Carbon monoxide. In: Dart RC. *Medical Toxicology*. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:1146-1154.
38. Phin N. Carbon monoxide poisoning (acute). *Clin Evid*. 2005;13: 1732-1743.
39. Juurlink DN, Buckley NA, Stanbrook MB, et al. Hyperbaric oxygen for carbon monoxide poisoning. *Cochrane Database of Systematic Reviews*; 2005; issue 1:CD002041. DOI: 10.1002/14651858.CD002041. pub2.
40. Buckley NA, Isbister GK, Stokes B, et al. Hyperbaric oxygen for carbon monoxide poisoning: a systematic review and critical analysis of the evidence. *Toxicol Rev*. 2005;24:75-92.
41. United States Department of Health and Human Services, Center for Medicare and Medicaid Services, National Coverage Determination Manual (Publication 100-3), NCD for hyperbaric oxygen therapy (manual section 20.29), revised April 1, 2003. Available at: <http://www.cms.hhs.gov/mcd>. Accessed January 23, 2006.
42. Sosiak T, Evans W. Hyperbaric medicine in Ontario: clinical overview, resource challenges. *Ontario Med Rev*. 2005;May:51-54.
43. Medicare Services Advisory Committee. Hyperbaric oxygen therapy: MSAC applications 1018-1020 assessment report: Canberra, Australia, 2001. Available at: [http://www.msac.gov.au/pdfs/reports/msac1018\\_1020.pdf](http://www.msac.gov.au/pdfs/reports/msac1018_1020.pdf). Accessed June 9, 2005.
44. Anonymous. *Hyperbare Sauerstofftherapie (HBO2) Zusammenfassender Bericht des Arbeitsausschusses "Ärztliche Behandlung" des Bundesausschusses der Ärzte und Krankenkassen über die Beratungen der Jahre 1999 und 2000 zur Bewertung der Hyperbaren Sauerstofftherapie gemäß §135 Abs.1 SGB V [Hyperbaric Oxygen Therapy (HBO<sub>2</sub>) Summary Report of the Working Committee on "Medical Treatment" of the Federal Committee of Physicians and Health Insurance Companies Covering Years 1999 and 2000 for the Evaluation of Hyperbaric Oxygen Therapy in Accordance with §135 Abs.1 SGB V]* [German]. Köln, Germany: Geschäftsführung des Arbeitsausschusses; 2000. Available at: [www.kbv.de/hta/1942.htm](http://www.kbv.de/hta/1942.htm). Accessed June 9, 2005.
45. Koren G, Sharav T, Pastuszak A, et al. A multicenter, prospective study of fetal outcome following accidental carbon monoxide poisoning in pregnancy. *Reprod Toxicol*. 1991;5:397-403.
46. Van Hoesen KB, Camporesi EM, Moon RE, et al. Should hyperbaric oxygen be used to treat the pregnant patient with acute carbon monoxide poisoning? A case report and literature review. *JAMA*. 1989;261:1039-1043.
47. Longo LD. The biological effects of carbon monoxide on the pregnant woman, fetus, and newborn infant. *Am J Obstet Gynecol*. 1977;129:69-103.
48. Sloan EP, Murphy DG, Hart R, et al. Complications and protocol considerations in carbon monoxide-poisoned patients who require hyperbaric oxygen therapy: report from a ten-year experience. *Ann Emerg Med*. 1989;18:629-634.
49. American College of Emergency Physicians. Clinical policy for the initial approach to patients presenting with acute toxic ingestion or dermal or inhalation exposure. *Ann Emerg Med*. 1999;33:735-761.
50. Schriger DL, Cantrill SV, Greene CS. The origins, benefits, harms, and implications of emergency medicine clinical policies. *Ann Emerg Med*. 1993;22:597-602.
51. Ducasse JL, Celsis P, Marc-Vergnes JP. Non-comatose patients with acute carbon monoxide poisoning: hyperbaric or normobaric oxygenation? *Undersea Hyperb Med*. 1995;22:9-15.
52. Gorman DF, Clayton D, Gilligan JE, et al. A longitudinal study of 100 consecutive admissions for carbon monoxide poisoning to the Royal Adelaide Hospital. *Anaesth Intensive Care*. 1992;20: 311-316.
53. Raphael JC, Chevret S, Driheme A, et al. Managing carbon monoxide poisoning with hyperbaric oxygen [abstract]. *J Toxicol Clin Toxicol*. 2004;42:455-456.
54. Thom SR. Hyperbaric oxygen therapy for carbon monoxide poisoning: is it time to end the debates? *Toxicol Rev*. 2005;24: 157-158.
55. Scheinkestel CD, Jones K, Myles PS, et al. Where to now with carbon monoxide poisoning? *Emerg Med Australas*. 2004;16: 151-154.
56. Weaver LK, Ramona OH, Chan KJ, et al. Carbon Monoxide Research Group, LDS Hospital, Utah in reply to Scheinkestel et al and Emerson: the role of hyperbaric oxygen in carbon monoxide poisoning. *Emerg Med Australas*. 2004;16:394-399.
57. Buckley NA, Isbister GK, Juurlink DN. Hyperbaric oxygen for carbon monoxide poisoning: evidence versus opinion. *Toxicol Rev*. 2005;24:159-160.
58. Weaver LK. Hyperbaric oxygen in carbon monoxide poisoning: conflicting evidence that it works. *BMJ*. 1999;319:1083-1084.
59. Scheinkestel CD, Tuxen DV, Bailey M, et al. Hyperbaric oxygen in carbon monoxide poisoning: authors of study clarify points that they made. *BMJ*. 2000;321:109.
60. Scheinkestel CD, Bailey M, Myles PS, et al. Letter: response to letters from volume 27(1), 2000. *Undersea Hyperbar Med*. 2000; 27:163-164.
61. Weaver LK, Valentine KJ, Hopkins RO. Carbon monoxide poisoning: risk factors for cognitive sequelae and the role of hyperbaric oxygen. *Am J Respir Crit Care Med*. 2007;176:491-497.
62. Annane D, Chevret S, Jars-Guinestre C, et al. Prognostic factors in unintentional mild carbon monoxide poisoning. *Intensive Care Med*. 2001;27:1776-1781.
63. Caravati EM, Adams CJ, Joyce SM, et al. Fetal toxicity associated with maternal carbon monoxide poisoning. *Ann Emerg Med*. 1988;17:714-717.
64. Elkharrat D, Raphael JC, Korach JM, et al. Acute carbon monoxide intoxication and hyperbaric oxygen in pregnancy. *Intensive Care Med*. 1991;17:289-292.
65. Norman CA, Halton DM. Is carbon monoxide a workplace teratogen? A review and evaluation of the literature. *Ann Occup Hyg*. 1990;34:335-347.
66. Margulies JL. Acute carbon monoxide poisoning during pregnancy. *Am J Emerg Med*. 1986;4:516-519.
67. Silverman RK, Montano J. Hyperbaric oxygen treatment during pregnancy in acute carbon monoxide poisoning: a case report. *J Reprod Med*. 1997;42:309-311.

68. Hollander DI, Nagey DA, Welch R, et al. Hyperbaric oxygen for the treatment of acute carbon monoxide poisoning in pregnancy: a case report. *J Reprod Med.* 1987;32:615-617.
69. Brown DB, Mueller GL, Golich FC. Hyperbaric oxygen treatment for carbon monoxide poisoning in pregnancy: a case report. *Aviat Space Environ Med.* 1992;63:1011-1014.
70. Hampson NB, Zmaeff JL. Outcome of patients experiencing cardiac arrest with carbon monoxide poisoning treated with hyperbaric oxygen. *Ann Emerg Med.* 2001;38:36-41.
71. Norkool DM, Kirkpatrick JN. Treatment of acute carbon monoxide poisoning with hyperbaric oxygen: a review of 115 cases. *Ann Emerg Med.* 1985;14:1168-1171.

Evidentiary Table.

Study	Year	Design	Intervention(s)/Test(s)/Modality	Outcome Measure/Criterion Standard	Results	Limitations/Comments	Class
Weaver et al <sup>10</sup>	2002	Randomized controlled trial (Design 1); double-blinded; N=152; patients of all severity included	All patients received $\geq 3$ h mask O <sub>2</sub> ; all patients received 3 sessions in HBO <sub>2</sub> chamber within 24 h; number of HBO <sub>2</sub> sessions in HBO <sub>2</sub> group: 3; maximum HBO <sub>2</sub> treatment pressure: 3.0 ATA first session, 2.0 ATA subsequent 2 sessions; control patients received sham HBO <sub>2</sub> to preserve blinding; block randomizations used	Primary outcome: neurologic sequelae at 6 wks defined as either symptoms+aggregate of 6 neuropsychological test scores $\geq 1$ SD below predicted or no symptoms+aggregate of 6 neuropsychological test scores $\geq 2$ SD below predicted; blinded assessment	Primary outcome: neurologic sequelae 6 wks after poisoning in 25.0% of HBO <sub>2</sub> -treated patients and 46.1% of controls (OR 0.39; 95% CI 0.20-0.78; <i>P</i> =0.007); NNT=4.8; incidence of neurologic sequelae decreased but still statistically significant at 6 and 12 mo; no significant difference between HBO <sub>2</sub> and control groups in overall/mean neuropsychological test scores, depression, activities of daily living, or subscores of the 36 item short form general health survey	Lost to enrollment/declined to participate: 54%; lost to follow-up: 5%; suicidal patients: 31%; mean time to treatment: 5.6 h;  Limitations: difference in baseline cerebellar dysfunction between the 2 groups; cerebellar dysfunction showed strong correlation to poor outcome; attempted control for cerebellar dysfunction with logistic regression was performed; control group with greater duration of CO exposure; high percentage (54%) of eligible patients "declined" contributing to selection bias; subjective component to primary outcome contributing to detection bias; study used block randomization	II

Evidentiary Table (continued).

Study	Year	Design	Intervention(s)/Test(s)/Modality	Outcome Measure/Criterion Standard	Results	Limitations/Comments	Class
Raphael et al <sup>12</sup>	1989	Randomized controlled trial (Design 1); N=343; (groups A0 and A1); patients with loss of consciousness excluded (7 mistakenly enrolled)	All patients received 6 h O <sub>2</sub> ; number of HBO <sub>2</sub> sessions in HBO <sub>2</sub> group: 1; maximum HBO <sub>2</sub> treatment pressure: 2.0 ATA; no use of sham HBO <sub>2</sub>	Symptom questionnaire; physical examination in some patients; no formal neuropsychological instruments; primary outcome: any sign or symptom of CO poisoning at 1-mo follow-up	Neurologic sequelae in 32.1% of HBO <sub>2</sub> -treated patients and 33.8% of controls (OR 0.93; 95% CI 0.56-1.53; <i>P</i> =0.84, NS); NNT=59	Lost to enrollment: 9%; lost to follow-up: 10%; suicidal: 0% (excluded); mean time to treatment: 6.2 h; separate arm of same trial randomized patients with loss of consciousness to 1 vs 2 HBO <sub>2</sub> treatments; parallel study (groups B1 and B2, N=286) of patients with loss of consciousness/coma not considered in analysis except as noted;  Limitations: blinded assessment not stated; large subjective component to primary outcome contributing to detection bias; no sham therapy for the HBO group	III

Evidentiary Table (continued).

Study	Year	Design	Intervention(s)/Test(s)/Modality	Outcome Measure/Criterion Standard	Results	Limitations/Comments	Class
Scheinkestel et al <sup>13</sup>	1999	Randomized controlled trial (Design 1); Double blinded; N=191; patients of all severity included	All patients received $\geq 3$ days of mask O <sub>2</sub> ; number of HBO <sub>2</sub> sessions in HBO <sub>2</sub> group: 3; up to 3 additional if symptoms persisted; maximum HBO <sub>2</sub> treatment pressure: 2.8 ATA each session; control patients received sham HBO <sub>2</sub> to preserve blinding	Primary outcome: persistent neurologic sequelae at the end of treatment defined as $\geq 2$ of 7 neuropsychological test scores $\geq 1$ SD below predicted; secondary outcome: delayed neurologic sequelae at 4 wks	Persistent neurologic sequelae in 74% of HBO <sub>2</sub> -treated patients and 68% of controls (OR 1.7; 95% CI 0.8-4.0; <i>P</i> =0.19, NS); number needed to harm=16.7; delayed neurologic sequelae in 4.8% of HBO vs 0% NBO group; no significant difference between HBO <sub>2</sub> and control groups in 6 of 7 neuro-psychological test scores after 3 treatments; no difference between groups in any test found at 1 mo, but inadequate follow-up rate	Lost to enrollment: not stated; lost to follow-up: 54%; suicidal patients: 69%; mean time to treatment: 7.1 h;  Limitations: poor follow-up at 1 mo; diminished generalizability because of high oxygen dose of control arm; study used cluster randomization	II (For persistent neurologic sequelae data)  X (for delayed neurologic sequelae data)

Evidentiary Table (continued).

Study	Year	Design	Intervention(s)/Test(s)/Modality	Outcome Measure/Criterion Standard	Results	Limitations/Comments	Class
Thom et al <sup>14</sup>	1995	Randomized controlled trial (Design 1); N=65; patients with loss of consciousness excluded	All patients received O <sub>2</sub> until asymptomatic; number of HBO <sub>2</sub> sessions in HBO <sub>2</sub> group: 1; maximum HBO <sub>2</sub> treatment pressure: 2.8 ATA; no use of sham HBO <sub>2</sub>	Primary outcome: development of a symptom+any amount of deterioration on $\geq 1$ of 6 neuropsychological test scores at any time after poisoning; secondary outcome: neuropsychological testing in asymptomatic patients	Neurologic sequelae in 0% of HBO <sub>2</sub> -treated patients (95% CI 0%-12%) and 23% of controls (95% CI 10%-42%); NNT=4.3; of asymptomatic patients, HBO <sub>2</sub> group performed better than control on 1 of 6 tests (trail making), but the statistical and clinical significances of this difference are uncertain	Lost to enrollment: 4%; lost to follow-up: 8%; suicidal patients: not stated; mean time to treatment: 2.0 h; primary outcome resolved in all patients by 77 days; Limitations: nonblinded enrollment; blinded assessment not stated; no sham therapy for HBO group; subjective component to primary outcome; unknown statistical significance of secondary outcome	III
Mathieu et al <sup>16</sup>	1996	Randomized controlled trial; not blinded; N=575	HBO <sub>2</sub> vs mask O <sub>2</sub> ; noncomatose	Not stated	Benefit from HBO <sub>2</sub> at 1 and 3 months (NNT=15.4); no benefit from HBO <sub>2</sub> at 1 y	Abstract only	X
Ducasse et al <sup>51</sup>	1995	Randomized controlled trial; not blinded; N=26	HBO <sub>2</sub> vs mask O <sub>2</sub>	EEG, CBF at rest and with acetazolamide challenge	No benefit from HBO <sub>2</sub> on EEG and CBF tests; slight benefit from HBO <sub>2</sub> on CBF reactivity to acetazolamide (cannot calculate NNT)	No clinical outcome measurements	X
Gorman et al <sup>52</sup>	1992	Not randomized (practice pattern changed by dates); N=100	1 or 3 treatments of HBO <sub>2</sub> vs mask O <sub>2</sub>	Unspecified neuropsychological tests	Benefit for 3 HBO <sub>2</sub> treatments vs 1 session; no benefit found for HBO <sub>2</sub> vs HBO	Because of small numbers in mask O <sub>2</sub> group (N=6), underpowered for this comparison	X

Evidentiary Table (continued).

Study	Year	Design	Intervention(s)/Test(s)/Modality	Outcome Measure/Criterion Standard	Results	Limitations/Comments	Class
Raphael et al <sup>53</sup>	2004	Randomized controlled trial; not blinded; N=179	HBO <sub>2</sub> vs mask O <sub>2</sub> ; no loss of consciousness	Patient reported symptoms	No benefit from HBO <sub>2</sub>	Abstract only	X
Weaver et al <sup>61</sup>	2007	Data from 1992 to 1999; not randomized; not blinded; included 147 patients from a previously published clinical trial and 91 patients who were eligible but were not enrolled in the study; 238 total patients included in analysis	75 patients received HBO <sub>2</sub> in the clinical trial; 163 patients did not receive HBO <sub>2</sub> ; 146 of the 163 received 100% O <sub>2</sub> for a mean time of 6.9 h; 17 of the 163 received no therapy after the CO exposure	Neuropsychiatric testing at 6 wks, 6 mo, and 12 mo; the primary outcome of the study was 6 wk cognitive sequelae, which was assumed to be related to the CO poisoning; in the patients who did not receive HBO <sub>2</sub> , univariate and multivariable analysis were used to identify risk factors for cognitive sequelae at 6 wks	In all 238 patients 37% (87/238) had sequelae at 6 wks; in the 75 HBO <sub>2</sub> patients, the rate was 24% (18/75) sequelae at 6 wks; in the 146 O <sub>2</sub> therapy only patients the rate was 41% (60/146); and in the 17 no therapy patients, the rate was 53% (9/17) sequelae at 6 wks; risk factors for 6 wk cognitive sequelae: age $\geq$ 36 y and CO exposure duration $\geq$ 24 h; risk factor reduction with HBO <sub>2</sub> therapy in patients $\geq$ 36 y: OR 0.3 (0.2-0.6)	The mixing of clinical trial data with data from patients not enrolled in the clinical trial makes this a large case series only; the determination of risk factor reduction for cognitive sequelae with HBO <sub>2</sub> therapy using a larger control group outside of a clinical trial should not provide results that are any more reliable than those found within the context of the clinical trial itself, and should not be assumed to be more accurate or representative of the results that could be obtained in clinical practice	III (for 6 wk cognitive sequelae)

**Evidentiary Table (continued).**

<b>Study</b>	<b>Year</b>	<b>Design</b>	<b>Intervention(s)/Test(s)/Modality</b>	<b>Outcome Measure/Criterion Standard</b>	<b>Results</b>	<b>Limitations/Comments</b>	<b>Class</b>
Hampson and Zmaeff <sup>69</sup>	2001	Consecutive patient case series; N=18	HBO <sub>2</sub> after resuscitation from CO-associated cardiac arrest	Survival to hospital discharge	No benefit from HBO <sub>2</sub> (all patients died); (survival rate 0%; 95% CI 0%-18.5%)	Small sample size	III

*ATA*, atmosphere absolute; *CBF*, cerebral blood flow; *CI*, confidence interval; *CO*, carbon monoxide; *EEG*, electroencephalogram; *h*, hour; *HBO<sub>2</sub>*, hyperbaric oxygen; *mo*, month; *NBO*, normobaric oxygen; *NNT*, number needed to treat; *NS*, not significant; *O<sub>2</sub>*, oxygen; *OR*, odds ratio; *SD*, standard deviation; *vs*, versus; *wks*, weeks; *y*, year.

**Appendix A.** Literature classification schema.\*

<b>Design/Class</b>	<b>Therapy<sup>†</sup></b>	<b>Diagnosis<sup>‡</sup></b>	<b>Prognosis<sup>§</sup></b>
1	Randomized, controlled trial or meta-analyses of randomized trials	Prospective cohort using a criterion standard	Population prospective cohort
2	Nonrandomized trial	Retrospective observational	Retrospective cohort Case control
3	Case series Case report Other (eg, consensus, review)	Case series Case report Other (eg, consensus, review)	Case series Case report Other (eg, consensus, review)

\*Some designs (eg, surveys) will not fit this schema and should be assessed individually.

<sup>†</sup>Objective is to measure therapeutic efficacy comparing  $\geq 2$  interventions.

<sup>‡</sup>Objective is to determine the sensitivity and specificity of diagnostic tests.

<sup>§</sup>Objective is to predict outcome including mortality and morbidity.

**Appendix B.** Approach to downgrading strength of evidence.

<b>Downgrading</b>	<b>Design/Class</b>		
	<b>1</b>	<b>2</b>	<b>3</b>
None	I	II	III
1 level	II	III	X
2 levels	III	X	X
Fatally flawed	X	X	X